However, the inclusion of broader EGFR‐mutated NSCLC patients allowed us to capture preferences from those who had experience receiving EGFR‐TKIs, thus yielding more accurate preferences of decision‐makers considering novel EGFR‐TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.